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Crystal packing and conformational comparison of known and new clofaziminium salts. 
Abstract Clofazimine (CFZ), is a water-insoluble antimycobacterial agent gaining attention as a 
multi-drug and extensively-drug resistant tuberculosis treatment. Novel salts of clofazimine are 
reported with fumaric, succinic, 2,4-dihydroxybenzoic and terephthalic acids as well as with 
saccharin. The salt structures were obtained by single-crystal X-ray diffraction. Salt with 2,4-
dihydroxybenzoic acid and with saccharin are solvated (methanol and acetonitrile respectively). 
Clofazimine reaction with terephthalic acid led to two cocrystals of salt, one solvated and a non-
solvated one. New clofaziminium salts were compared to the currently known ones in terms of crystal 
packing and clofazimine/ium conformations. Clofaziminium hydrogen succinate presents 
isostructurality with clofaziminium hydrogen malonate, an already described salt. In structures of 
clofaziminium terephthalate terephthalic acid cocrystal of salt, solvent evaporation leads to packing 
and H-bonding modifications. In all structures, clofaziminium conformation is quite well conserved 
and steric hindrance is observed around the protonated site. Conformational optimization of 
clofaziminium reveals that this steric hindrance energy penalty is compensated by H-bond interactions 
with clofaziminium counter-ion. 
Keywords: Clofazimine; salt; conformational comparison; crystal packing comparison, 
counter-ion effect on clofaziminium conformation.  
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1. Introduction 
Clofazimine (CFZ, Figure 1) is an antimycobacterial and anti-inflammatory agent belonging to the 
family of riminophenazine. First synthesized by Barry et al. in 1957, clofazimine has been used 
worldwide in combination with dapsone and rifampicin as a treatment against leprosy thanks to its 
bactericidal effect against M. leprae (Barry et al., 1957). Besides its anti-leprotic properties, 
clofazimine is also a drug used to treat multi-drug resistant (MDR) tuberculosis (World Health 
Organization, 2015). Recently, the apparition of resistant strains of M. tuberculosis resulted in a 
renewal of interest for this drug, since clofazimine exhibit good in vitro activity against MDR 
Mycobacterium tuberculosis (Redd et al., 1999; Cholo et al., 2012). However, clofazimine is a very 
lipophilic molecule resulting in poor solubility and very long half-time (around 70 days in human 
(Levy, 1974)). This property is associated with undesirable effects such as recrystallization of the 
compound in the liver and in macrophages (Horstman et al., 2017; Keswani et al., 2015) as well as 
bioaccumulation resulting in strong side effects, skin discoloration (Job et al., 1990) and poor 
compliance. Currently, clofazimine has a limited clinical use probably because of its lack of 
bioavailability and so its limited efficiency. Several methods were investigated to increase 
clofazimine solubility with various success. Among those were described, for example, clofazimine 
complexation in cyclodextrins (Salem et al., 2003), preparation of amorphous solid dispersion 
(Narang & Srivastava, 2002) or clofazimine co-administration with lipid vehicles (O’Reilly et al., 
1994). 
Because clofazimine is gaining attention as a MDR and extensively drug-resistant M. tuberculosis 
treatment, groups of researchers recently tried new approaches to improve its pharmacological 
properties. As clofazimine is a weakly basic compound (pKa 9.29 (Keswani et al., 2015)), a possible 
strategy to increase its solubility is salt formation. In 2012, G. Bolla et al. published eight structures of 
salts, one of these, clofazimine mesylate was 99 time more soluble in 60% EtOH-water media than 
pure clofazimine (Bolla & Nangia, 2012). In 2016, Bannigan et al. investigated clofazimine 
polymorphism (Bannigan et al., 2016) and more recently they studied the solubility of several 
clofaziminium salts (Bannigan et al., 2017). Here, we report seven new structures: three salts 
(clofaziminium hydrogen fumarate, CFZ-NH+-FA- (1:1), clofaziminium hydrogen succinate, CFZ-
NH+-SA- (1:1)) and clofaziminium saccharinate, CFZ-NH+-SACC- (1:1), two solvated salts 
(clofaziminium 2,4-dihydroxybenzoate methanol solvate, CFZ-NH+-2,4DHBA--MeOH (1:1:1) and 
clofaziminium saccharinate acetonitrile solvate, CFZ-NH+-SACC--MeCN (1:1:1.4)), and two 
cocrystals of salt (structure composed of one cation, one anion and a non-ionized molecule). One is 
nonstoichiometrically solvated and the other is non-solvated (clofaziminium terephthalate terephthalic 
acid solvate CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) and clofaziminium terephthalate 
terephthalic acid, CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5)). Those new salts are compared to the 
currently known ones in terms of crystal packing and clofaziminium conformation. 
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Figure 1 (a) Numbering scheme of clofazimine/ium(CFZ/CFZ-NH+) (torsions angles: T1, C8-N3-
C19-C20; T2, C9-N4-C25-C27; T3, C12-N1-C13-C18 T4, H-N4-C9-C8 and T5, H-N3-C8-C9) and 
selected acids in the present work : fumaric acid, succinic acid, DL-malic acid, 2,4-dihydroxybenzoic 
acid, saccharin, L-aspartic acid, terephthalic acid and citric acid. (b) Acids crystallized with 
clofazimine by G. Bolla et al. (Bolla & Nangia, 2012) and (c) acids crystallized with clofazimine by 
P. Bannigan et al. (Bannigan et al., 2017). CFZ-NH+-CIT- (1:1) salt was already described by P. 
Bannigan et al. (Bannigan et al., 2017), in the present study salt formation of CFZ/CIT in 2/1 and 3/1 
molar ratios was attempted. 
2. Experimental section 
2.1. Materials  
Clofazimine was purchased from TCI Europe N.V. (Zwindrecht, Belgium), fumaric, 2,4-
dihydroxybenzoic and terephthalic acids as well as saccharin were from Sigma-Aldrich (Steinheim, 
Germany), while succinic acid was purchased from J.T. Baker Chemicals (Deventer, Holland). 
Crystallization solvents (acetonitrile, methanol, ethyl acetate, and diethyl ether) are commercially 
available (Acros Organics, Geel, Belgium) and were used without further purification. 
2.2. General routes for clofazimine salification. 
All samples were prepared by liquid-assisted grinding (LAG) (Frišcic et al., 2009; Shan et al., 2002; 
Trask et al., 2004; James et al., 2012) with a Retsch MM 400 Mixer Mill apparatus with two grinding 
jars in which five 2mL Eppendorf tubes can be installed. Each sample grinding was performed with 
around 100 mg of powder (75mg of clofazimine and corresponding mass of acid to respect 1/1, 2/1 or 
3/1 CFZ/acid molar ratios) in presence of 6 to 8 stainless steel grinding balls (2 mm diameter). 
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Following solvents were used for liquid-assisted ball milling: MeCN for CFZ/FA, CFZ/SA, 
CFZ/SACC, CFZ/L-ASP, and CFZ/DL-MAL equimolar mixtures as well as for CFZ/CA 2/1 and 3/1 
mixtures; MeOH for CFZ/2,4-DHBA 1/1 and EtOAc for CFZ/TRPTA.  Powders leading to new 
diffraction patterns were then involved in crystallization assays by slow evaporation at room 
temperature in a mixture of MeCN and MeOH, except for CFZ/TRPTA 1/1 powder for which EtOAc 
was used. For CFZ/DL-MAL crystallization in Et2O at 4°C as well as in MeCN at room temperature 
was also attempted. 
2.3. Single-crystal X-ray diffraction (SCXRD). 
Selected crystals of suitable size were mounted on an Oxford Diffraction Gemini Ultra R system (4-
circle kappa platform, Ruby CCD detector). By default Mo radiation was used for data collection, but 
when the crystal diffracted poorly, Cu radiation was used as it allows enhanced intensities with this 
Gemini system. In consequence, data were collected using Mo 𝐾𝛼 (𝜆 = 0.71073 Å) (for CFZ-NH+-
SA- (1:1), CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) and CFZ-NH+-TRPTA2--TRPTA 
(1:0.5:0.5)) or Cu 𝐾𝛼 (𝜆 = 1.54184 Å) for the other salts (CFZ-NH+-FA- (1:1), CFZ-NH+-2,4DHBA-
-MeOH (1:1:1), CFZ-NH+-SACC- (1:1) and CFZ-NH+-SACC--MeCN (1:1:1.4)). Full data sets 
were collected either at room temperature (CFZ-NH+-FA- (1:1), CFZ-NH+-SA- (1:1), CFZ-NH+-
SACC- (1:1), CFZ-NH+-2,4DHBA--MeOH (1:1:1) and CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5)) 
or at 100K (CFZ-NH+-SACC--MeCN (1:1:1.4) and CFZ-NH+-TRPTA2--TRPTA-solvent 
(1:0.5:0.5:x)). Analytical absorption correction was performed on SCXRD data for structures CFZ-
NH+-FA- (1:1), CFZ-NH+-SA- (1:1), CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) and CFZ-
NH+-TRPTA2--TRPTA (1:0.5:0.5) using CrysAlis PRO 1.171.38.46 ((Rigaku Oxford Diffraction, 
2015)) and 1.171.39.46 ((Rigaku Oxford Diffraction, 2018)). Analytical numeric absorption 
correction using a multifaceted crystal model based on expressions derived by R.C. Clark & J.S. Reid. 
(Clark, R. C. & Reid, J. S. (1995). Acta Cryst. A51, 887-897). Empirical absorption correction using 
spherical harmonics, implemented in SCALE3 ABSPACK scaling algorithm. Gaussian absorption 
correction was performed on SCXRD data for structures CFZ-NH+-SACC--MeCN (1:1:1.4) and 
CFZ-NH+-2,4DHBA--MeOH (1:1:1) using CrysAlis PRO 1.171.39.46 ((Rigaku Oxford Diffraction, 
2018)). Numerical absorption correction based on gaussian integration over a multifaceted crystal 
model. Empirical absorption correction using spherical harmonics, implemented in SCALE3 
ABSPACK scaling algorithm. Multi-scan absorption correction was performed on SCXRD data for 
structure CFZ-NH+-SACC- (1:1) (CrysAlis PRO 1.171.39.46 (Rigaku Oxford Diffraction, 2018) 
Empirical absorption correction using spherical harmonics, implemented in SCALE3 ABSPACK 
scaling algorithm.). Structures were solved by dual-space method using SHELXT (Sheldrick, 2015b) 
and then refined by least square method using SHELXL-2018/1 (Sheldrick, 2015a) within Olex2 
(Dolomanov et al., 2009) and SHELXLE (Hübschle et al., 2011). Non-hydrogen atoms were 
anisotropically refined. Hydrogen atoms implied in strong hydrogen bonds were localized by Fourier 
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difference maps while those not implied in H-bonds were refined as riding body by fixing thermal 
ellipsoids to 1.2 times the one of preceding atom (or 1.5 for methyl group). Several structures are 
disordered, those structures are: CFZ-NH+-SA- (1:1) (C29 and C30 of hydrogen succinate), CFZ-
NH+-2,4DHBA--MeOH (1:1:1) (2,4DHBA- and MeOH show minor disorder (hydrogen atom of the 
OH group of disordered MeOH could not be localised by Fourier difference map)), CFZ-NH+-SACC- 
(1:1) (SACC- is disordered) and CFZ-NH+-SACC--MeCN (1:1:1.4) (chlorophenyl, 1, on Figure 1 and 
isopropyl groups of clofazimine as well as acetonitrile, which is disordered over three positions). The 
structure of cocrystal of salt CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) presents solvent 
accessible voids forming channels but solvent of crystallization could not be unambiguously assigned. 
Therefore, the original reflection file of CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5) was submitted to 
the PLATON SQUEEZE procedure (Spek, 2015). Total potential accessible void volume was 
determined as 489 Å³ with an electron count per cell of 141, which corresponds to 2.9 EtOAc 
molecules in the unit cell. Only low resolution data collection (till 0.9Å) could be performed for the 
structure CFZ-NH+-SACC- (1:1) because crystals were obtained by desolvating crystals of CFZ-
NH+-SACC--MeCN (1:1:1.4) (other methods did not lead to unsolvated crystals). 
2.4. Powder X-ray diffraction (PXRD). 
Powder diffraction data were collected on an X’PERT PRO PANalytical Bragg-Brentano 
diffractometer with Cu 𝐾𝛼 radiation (𝜆 = 1.54184 Å) at 45 kV and 30 mA with a X’Celerator linear 
detector. Data were collected from 4 to 40° 2 𝜃  angles with a step size of 0.0167°. Variable 
temperature measurement using AntonPaar system were realized at 25°C and then between 30 and 
200°C with data collection each 10°C. Calculated powder patterns from SCXRD data were generated 
with the program Mercury CSD 3.10.2 (Macrae et al., 2008). 
2.5. Search in the Cambridge structural database (CSD).  
Known structures of clofazimine and clofaziminium salts were retrieved from CSD using ConQuest. 
In total 15 structures implying clofazimine were retrieved (clofazimine, clofaziminium salts and/or 
solvates). Three other clofaziminium salts (CFZ-NH+-CIT- (1:1), CFZ-NH+-H2PO4--H2O (1:1:0.25) 
and CFZ-NH+-HSO4--MeOH (1:1:1)) were available as supplementary data from the publication of 
Bannigan et al.) (Bannigan et al., 2017). All these 18 structures were further analyzed. 
2.6. Structure visualization, voids calculation and full interaction maps (FIMs) generation. 
Structures were visualized with the CCDC Mercury CSD 3.10.2 software and images were generated 
using the same program (Macrae et al., 2008). Figures illustrating voids were generated with the 
display voids option in CCDC Mercury CSD 3.10.2 with a probe radius of 1.2 Å and a grid spacing of 
0.1 Å. For the structures of CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) and CFZ-NH+-
TRPTA2--TRPTA (1:0.5:0.5), least square planes passing through atoms N1, C5 and C6 of 
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clofaziminium were calculated with CCDC Mercury CSD 3.10.2 in order to compare crystal packing 
of the two structures. Full interaction maps were generated within CCDC Mercury CSD 3.10.2. 
Probes used for FIMs generation were uncharged NH nitrogen, alcohol oxygen, and carbonyl oxygen 
with a contour level of 6.0. FIMs were generated using coordinates of a clofazimine molecule (from 
polymorph DAKXUI03) (Figure 2a), a clofaziminium ion (GESHET, CFZ-NH+-MSA--H2O (1:1:1)) 
(Figures 2b and 6a) and of a clofaziminium ion from CFZ-NH+-CIT- (1:1) (Figure 6b) (for those 
salts, only clofaziminium was considered for FIMs generation). 
2.7. Crystal packing comparison. 
Crystal packing comparison and figure of crystal lattice overlay were performed with the crystal 
packing similarity tool in CCDC Mercury (Macrae et al., 2008) with a packing shell size of 15 
molecules and a distance and angle tolerance of 30% and 30° respectively. Molecular differences and 
structure inversion were allowed while bond types, hydrogen positions, atom’s hydrogen count and 
atom’s bond count were ignored. As multi-components systems with different counter-ions were 
analyzed, the smallest molecular component was ignored for packing overlay. Only CFZ-NH+-SA- 
(1:1) showed a molecular overlay of 15 molecules out of 15 with CFZ-NH+-MLN- (1:1) (GESGOC). 
2.8. Melting point measurement.  
Melting points of non-solvated salts were determined visually by using a Büchi Melting point B545 
apparatus. 
2.9. Clofazimine/clofaziminium overlay. 
For each structure of clofazimine/clofaziminium salt (structures of this paper, and these found in the 
literature) coordinates of one molecule/ion of clofazimine/clofaziminium were selected from 
asymmetric unit. All selected molecules/ions were overlaid using the Small Molecule overlay tool in 
Discovery Studio v18 (Dassault Systèmes BIOVIA, 2016). Neither rotatable bonds nor flexible 
torsions were allowed and the alignment by consensus was performed by a field 50% steric and 50% 
electrostatic. 
2.10. Conformational analysis by quantum mechanics calculations. 
Optimization calculations of clofazimine and clofaziminium were performed using density functional 
theory (DFT) with the m06 functional (Zhao & Truhlar, 2008) and the 6-311G(d) basis set (Frisch et 
al., 2016). To this aim coordinates of the neutral form of clofazimine was extracted from DAKXUI03 
structure while coordinates of the protonated form (clofaziminium) were extracted from CFZ-NH+-
Cl- (1:1) (LABQUD) crystal structure.  
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3. Results and discussion 
Acidic compounds to react with clofazimine were selected after full interaction map analysis of 
clofazimine and clofaziminium. Salification assays were performed by liquid-assisted grinding and 
powders leading to new diffraction patterns were used in crystallization experiments. In this section, 
results obtained after salification assays and PXRD measurement are first summarized. Then, new 
structures are described and compared to the known ones in terms of interaction and crystal packing 
similarity. Finally, clofazimine and clofaziminium conformations are compared with each other and 
with the optimized conformations of clofazimine and clofaziminium (in presence or absence of its 
counter-ion). 
3.1. Full interaction maps analysis of CFZ and CFZ-NH+ and choice of acids to react with CFZ. 
Full interaction maps (FIMs) were generated to investigate the propensity of 
clofazimine/clofaziminium to interact with uncharged NH nitrogen, alcohol oxygen, and carbonyl 
oxygen. FIMs calculations at the 6.0 contour level indicate two main sites of interaction, namely 
around nitrogen atoms N3 and N4 for the first site and around N2 for the second site (Figure 2). Both 
sites are common for clofazimine and clofaziminium. However, the interaction between the first site 
and carbonyl oxygen or OH probes is stronger in the case of clofaziminium (Figure 2 (a) and (b)). 
From those FIMs analyses, it can be assumed that clofazimine should be able to form salts with 
several carboxylic acids. Clofaziminium salts with organic acids (methanesulfonic acid, maleic acid, 
isonicotinic acid, nicotinic acid, salicylic acid and malonic acid) were reported by G. Bolla et al. 
(Bolla & Nangia, 2012) while Bannigan et al. obtained clofaziminium salts by reacting clofazimine 
with organic and inorganic acids (hydrochloric acid, sulphuric acid, nitric acid, oxalic acid, 
phosphoric acid, citric, formic and acetic acids) (Bannigan et al., 2017). Here, other carboxylic acids 
(which should protonate N4 of CFZ) were selected to form new clofaziminium salts. 2,4DHBA and 
DL-MAL were selected because of their alcohol functions which could potentially interact with the 
N2 site of CFZ. L-ASP was chosen to assess the ability of clofazimine to react with amino-acids 
(reaction is expected with the carboxylic acid of the side chain). CIT was selected to be reacted in 2/1 
and 3/1 CFZ/CIT molar ratios with CFZ to investigate CIT propensity to be unprotonated at multiple 
sites. Moreover, the potential new structures of CFZ/CIT could be compared to the one obtained by 
Bannigan et al. (Bannigan et al., 2017). FA and SA were chosen for their similarity and so for their 
potential ability to form isostructural structures. TRPTA was selected to compare CFZ salts obtained 
with aliphatic vs aromatic dicarboxylic acids. Finally, saccharin was chosen to evaluate its propensity 
to react with clofazimine. Indeed, saccharin has acidic properties despite its lack of carboxylic acid 
function. Moreover, except terephthalic and 2,4-dihydroxybenzoic acids, the selected compounds are 
classified either as food additives (Ash & Ash, 2008) or as generally regarded as safe (GRAS) (FDA, 
2018). 
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Figure 2 FIMs calculated around clofazimine (a) and clofaziminium (b). Carbonyl oxygen, 
uncharged NH and alcohol OH probes in red, blue and orange respectively. 
3.2. CFZ salification assays and corresponding results. 
All liquid-assisted ball milling led to solids with new powder patterns except for CFZ/L-ASP 1/1 
(Figure S2). Crystallization assays of all powders except this one were attempted and only, CFZ/DL-
MAL did not crystallize in our conditions. Single-crystal X-ray diffraction data were collected on 
crystals of suitable size. Seven new clofaziminium salt structures were refined. Among those, three 
are salts (clofaziminium hydrogen fumarate, CFZ-NH+-FA- (1:1), clofaziminium hydrogen succinate, 
CFZ-NH+-SA- (1:1) and clofaziminium saccharinate, CFZ-NH+-SACC- (1:1)), two are solvated salts 
(clofaziminium 2,4-dihydroxybenzoate methanol solvate, CFZ-NH+-2,4DHBA--MeOH (1:1:1) and 
clofaziminium saccharinate acetonitrile solvate, CFZ-NH+-SACC--MeCN (1:1:1.4)), and two are 
cocrystals of salt (structure composed of one cation, one anion, and a non-ionized molecule). One is 
nonstoichiometrically solvated and the other is non-solvated (clofaziminium terephthalate terephthalic 
acid solvate CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) and clofaziminium terephthalate 
terephthalic acid, CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5)). The latter was obtained by slowly drying 
corresponding solvated crystals at room temperature. Crystals of CFZ/CIT 2/1 were obtained. 
However, the structure is intrinsically disordered and could not be refined even using data collected at 
100 K. Its cell parameters and were determined (a: 19.2962 (5), b: 12.3140 (3), c: 23.9105 (6); 𝛼: 90, 
𝛽: 110.667 (3), 𝛾: 90) and Powder pattern of the as synthesized product matches the one calculated 
from single-crystal data (Figure S2). Finally, CFZ/CIT 3/1 has a powder pattern highly similar to the 
one obtained after grinding CFZ/CIT 2/1. However, some new peaks are observed (Figure S2). 
Crystallization assays of CFZ/CIT 3/1 led to crystals of CFZ/CIT 2/1. Results of CFZ salification 
assays are summarized in Table 1. 
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Table 1 Clofazimine salification assays and corresponding results.  
Acid pKas (Haynes) CFZ/Acid ratio New PXRD? Crystals? Structure refined? 
FA 3.02; 4.38 1/1 yes yes yes 
SA 4.21; 5.64 1/1 yes yes yes 
2,4-DHBA 3.11 1/1 yes yes yes 
DL-MAL 3.40; 5.11 1/1 yes no no 
SACC 
1.94 (Rowe et 
al., 2006) 
1/1 yes yes yes 
L-ASP 1.99; 3.90 1/1 no no no 
TRPTA 3.54; 4.34 1/1 yes yes yes 
CIT 
3.13; 4.76; 
6.40 
2/1 
3/1 
yes 
yes 
yes 
yes** 
no* 
no 
* Structure of CFZ-NH+- CIT- (2:1) is intrinsically disordered. ** Crystallized as CFZ-NH+- CIT- (2:1). 
3.3. Crystal packing description of new CFZ salts. 
3.3.1. CFZ-NH+-FA- (1:1) salt.  
Clofaziminium hydrogen fumarate salt (Figure 3 (a)) crystallizes in 𝑃2ଵ/𝑐 space group (Table 3). 
Proton transfer between fumaric acid (O3) and the isopropyl imine of CFZ (N4) occurs. As already 
observed by P. Bannigan et al. (Bannigan et al., 2017), this proton transfer is accompanied  by an 
increase of the iminium angle (angle C9-N4-C25 = 126.02(18)) in comparison with the one of the 
uncharged clofazimine (C9-N4-C25 around 120° (Table S3)). A 𝑅ଶଵ(7)  H-bond motif is observed 
between FA- and CFZ-NH+ (N4+-H⋯O3- and N3-H⋯O3-) (Table S2). Hydrogen fumarate forms 
chains along the a-axis through H-bonds (𝐶ଵଵ(7) motif, O1-H⋯O3-) (Table S2). A 𝐷(2) motif is also 
present (N3-H⋯O2) (Table S2). CFZ-NH+ are stacked along a-axis in a head-to-tail fashion. PXRD 
pattern of the as synthesized powder matches the one calculated from single-crystal data (Figure S1). 
Melting point of CFZ-NH+-FA- (1:1) is 246°C, which is much higher than the starting API (Table 2). 
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Table 2  Melting points of non-solvated clofaziminium salts. 
Compound analyzed Melting point (°C) 
CFZ (DAKXUI01) 219 
Fumaric acid 210 * (Temesvári et al., 
1971)  
Succinic acid 186.9 
Saccharin 229.5 (Basavoju et al., 
2008) 
Terephthalic acid 276 * (Kimyonok & 
Ulutürk, 2016) 
CFZ-NH+-FA- (1:1) 246  
CFZ-NH+-SA- (1:1)- 214 
CFZ-NH+-SACC- (1:1) 252 
CFZ-NH+-TRPTA2--TRPTA 
(1:0.5:0.5) 
240 
* sublimation 
3.3.2. CFZ-NH+-SA- (1:1) salt.  
Clofaziminium hydrogen succinate salt (Figure 3 (b)) crystallizes in 𝑃1ത space group (Table 3). Proton 
transfer between succinic acid (O1) and the isopropyl imine of CFZ (N4) occurs, which is confirmed 
by bond distances reflecting resonance in the carboxylate and by an increase of the iminium angle 
(Table S3). A 𝑅ଶଵ(7) H-bond motif is observed between SA- and CFZ-NH+ (N4+-H⋯O1- and N3-
H⋯O1-) and an intramolecular H-bond is also present in hydrogen succinate ion (𝑆ଵଵ(7) motif, O4-
H⋯O2-) (Table S2). 2D sheets are formed through weak C-H⋯O and C-H⋯Cl H-bonds (Table S2). 
PXRD pattern of the as synthesized product matches the one calculated from single-crystal data 
(Figure S1). This salt melts at 214°C, this melting point is 5°C less than the one of the starting API 
CFZ (Table 2). 
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Figure 3  H-bond interactions in the structures of CFZ-NH+-FA- (1:1) (a), CFZ-NH+-SA- (1:1) (b), 
CFZ-NH+-SACC--MeCN (1:1:1.4) (c), CFZ-NH+-SACC- (1:1) (d) CFZ-NH+-2,4DHBA--MeOH 
(1:1:1) (e), CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) (f) and CFZ-NH+-TRPTA2--TRPTA 
(1:0.5:0.5) (g). Ellipsoids are drawn at the 50% probability level. 
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Table 3 Experimental details.  
Experiments were carried out using an Xcalibur, Ruby, Gemini Ultra diffractometer. H atoms were treated by a 
mixture of independent and constrained refinement.  
 CFZ-NH+-FA- (1:1) CFZ-NH+-SA- (1:1)  CFZ-NH+-SACC--MeCN (1:1:1.4) 
Crystal data    
Chemical formula C27H23Cl2N4+·C4H3O4- C27H23Cl2N4+·C4H5O4- C27H23Cl2N4+·C7H4NO3S-· 
1.393(C2H3N) 
Mr 589.46 591.47 713.78 
Crystal system, space group Monoclinic, P21/c Triclinic, P1ത Triclinic, P1ത 
Temperature (K) 295 295 100 
a, b, c (Å) 7.47882 (9), 26.0041 
(3), 14.78241 (16) 
10.6376 (6), 12.2781 (5), 
12.7975 (8) 
7.9970 (3), 13.5824 (3), 16.6638 
(7) 
, ,  (°) 90, 102.5075 (12), 90 90.079 (4), 113.211 (6), 
108.284 (4) 
80.214 (3), 80.034 (4), 83.036 
(3) 
V (Å3) 2806.65 (6) 1443.57 (15) 1748.87 (11) 
Z 4 2 2 
Radiation type Cu K Mo K Cu K 
 (mm-1) 2.45 0.27 2.61 
Crystal size (mm) 0.57 × 0.13 × 0.04 0.57 × 0.42 × 0.03 0.70 × 0.26 × 0.05 
Data collection    
Absorption correction Analytical Analytical Gaussian 
 Tmin, Tmax 0.502, 0.915 0.897, 0.990 0.295, 1.000 
No. of measured, 
independent and observed 
[I > 2(I)] reflections 
15078, 4944, 4394   10778, 5090, 3520   17257, 6202, 5378   
Rint 0.021 0.022 0.033 
(sin /)max (Å-1) 0.597 0.595 0.598 
Refinement    
R[F2 > 2(F2)], wR(F2), S 0.049, 0.136, 1.01 0.045,  0.122, 1.03 0.053,  0.142, 1.05 
No. of reflections 4944 5090 6202 
No. of parameters 383 412 594 
No. of restraints 0 4 137 
𝜌max, Δ𝜌min (e Å-3) 0.46, -0.51 0.24, -0.24 0.61, -0.67 
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 CFZ-NH+-SACC-  
(1:1) 
CFZ-NH+-
2,4DHBA--MeOH 
(1:1:1) 
CFZ-NH+-TRPTA2-
- TRPTA-solvent 
(1:0.5:0.5:x) 
CFZ-NH+-TRPTA2-
- TRPTA  
(1:0.5:0.5) 
Crystal data 
Chemical formula C27H23Cl2N4+· 
C7H4NO3S- 
C27H23Cl2N4+· 
C7H5O4-·CH4O 
C27H23Cl2N4+· 
0.5(C8H4O42-)· 
0.5(C8H6O4) 
C27H23Cl2N4+· 
0.5(C8H4O42-) 
·0.5(C8H6O4) 
Mr 656.56 659.54 639.51 639.51 
Crystal system, space group Triclinic, P1ത Triclinic, P1ത Triclinic, P1ത Triclinic, P1ത 
Temperature (K) 295 295 100 295 
a, b, c (Å) 8.2115 (7), 
13.5327 (12), 
14.325 (3) 
9.4861 (4), 12.5322 
(5), 15.3641 (5) 
11.7990 (4), 12.0736 
(4), 14.6803 (5) 
10.4028 (3), 10.8454 
(3), 15.4229 (5) 
, ,  (°) 89.04 (1), 88.864 
(10), 83.781 (7) 
98.415 (3), 103.379 
(3), 110.450 (4) 
72.472 (3), 80.688 
(3), 72.030 (3) 
71.183 (3), 73.984 
(3), 76.148 (2) 
V (Å3) 1582.0 (3) 1612.41 (12) 1891.44 (12) 1561.33 (9) 
Z 2 2 2 2 
Radiation type Cu K Cu K Mo K Mo K 
 (mm-1) 2.82 2.22 0.21 0.25 
Crystal size (mm) 0.54 × 0.29 × 0.05 0.49 × 0.12 × 0.06 0.57 × 0.39 × 0.26 0.72 × 0.48 × 0.41 
Data collection 
Absorption correction Multi-scan Gaussian  Analytical Analytical  
 Tmin, Tmax 0.549, 1.000 0.539, 0.991 0.917, 0.960 0.886, 0.921 
No. of measured, 
independent and observed 
[I > 2(I)] reflections 
7488, 3783, 2265 15458, 5692, 4965   20823, 11543, 9100   13059, 5704, 4554   
Rint 0.038 0.021 0.022 0.018 
(sin /)max (Å-1) 0.526 0.597 0.714 0.602 
Refinement 
R[F2 > 2(F2)], wR(F2), S 0.064,  0.190,  
1.08 
0.037, 0.111, 1.04 0.044, 0.118, 1.03 0.040, 0.109, 1.02 
No. of reflections 3783 5692 11543 5704 
No. of parameters 525 555 420 420 
No. of restraints 483 66 0 0 
𝜌max, 𝜌min (e Å-3) 0.23, -0.22 0.24, -0.32 0.41, -0.30 0.23, -0.27 
Computer programs: CrysAlis PRO 1.171.38.46 (Rigaku OD, 2015), CrysAlis PRO 1.171.39.46 (Rigaku OD, 
2018), SHELXT (Sheldrick, 2015), SHELXT 2014/5 (Sheldrick, 2014), SHELXL2016/6 (Sheldrick, 2016). 
  
Acta Crystallographica Section B    research papers 
IMPORTANT: this document contains embedded data - to preserve data integrity, please ensure where possible that the IUCr 
Word tools (available from http://journals.iucr.org/services/docxtemplate/) are installed when editing this document.  14 
 
3.3.3. (CFZ-NH+)1(SACC-)1(MeCN)1.4 solvated salt.  
Clofaziminium saccharinate acetonitrile solvated salt (Figure 3 (c)) crystallizes in 𝑃1ത space group 
(Table 3). Proton transfer between saccharin (N5) and the isopropyl imine of CFZ (N4) occurs and is 
confirmed by an increase of the iminium angle (Table S3). Acetonitrile solvate is disordered over 
three positions (first, second and third position occupancies were refined to the following values 
0.4640, 0.4890 and 0.440). A 𝑅ଶଶ(9) H-bond motif is observed between SACC- and CFZ-NH+ (N4+-
H⋯O3 and N3-H⋯N5- (Figure 3 (c) and Table S2)). Weak C-H⋯O H-bonds stabilize head-to-tail 
stacking of CFZ-NH+ (Table S2).  
3.3.4. CFZ-NH+-SACC- (1:1) salt 
Clofaziminium saccharinate (Figure 3 (d)) was obtained by drying crystals of CFZ-NH+-SACC--
MeCN (1:1:1.4) at room temperature. The unsolvated salt (CFZ-NH+-SACC- (1:1)) crystallizes in 
𝑃1ത space group (Table 3). Proton transfer between saccharin (N5) and the isopropyl imine of CFZ 
(N4) occurs and is confirmed by an increase of the iminium angle (Table S3). A 𝑅ଶଵ(7) H-bond motif 
is observed between SACC- and CFZ-NH+ (N4+-H⋯N5- and N3-H⋯N5- (Figure 3 (c) and Table S2)). 
Weak C-H⋯O H-bonds stabilize head-to-tail stacking of CFZ-NH+ (Table S2). It is interesting to 
notice that liquid-assisted grinding experiment leads to the unsolvated salt. Indeed, the powder pattern 
of the as synthesized product (CFZ/SACC 1/1 LAG MeCN) matches the one calculated from SCXRD 
data of CFZ-NH+-SACC- (1:1) and not the one calculated from SCXRD data of CFZ-NH+-SACC--
MeCN (1:1:1.4). 
3.3.5. CFZ-NH+-2,4DHBA--MeOH (1:1:1) solvated salt.  
Clofaziminium 2,4-dihydroxybenzoate methanol solvated salt (Figure 3 (e)) crystallizes in 𝑃1ത space 
group (Table 3). Proton transfer between 2,4-dihydroxybenzoic acid (O1) and the isopropyl imine of 
CFZ (N4) is confirmed by bond distances reflecting resonance in the carboxylate and by an increase 
of the iminium angle in comparison with the unprotonated form of clofazimine (Table S3). MeOH 
and 2,4-DHBA- are slightly disordered. A 𝑅ଶଵ(7) H-bond is observed between 2,4-DHBA- and CFZ-
NH+ (N4+-H⋯O1A- and N3-H⋯O1A- as well as N4+-H⋯O1B- and N3-H⋯O1B-) (Table S2). An 
intramolecular H-bond is also present in 2,4-dihydroxybenzoate (𝑆ଵଵ(6) motif, O3A-H⋯O2A-  as well 
as O3B-H⋯O2B-) (Table S2). Methanol molecules serve as a bridge between two 2,4-DHBA-. 
Indeed, a 𝐶ଶଶ(8) motif (O4A-H⋯O5A and O5A-H⋯O3A) is observed (Table S2) (Figure 4). In the 
second position of 2,4DHBA- and MeOH (disordered), the H- bond interactions form between O4B-
H⋯O5B  and O5B-H ⋯ O4B (Table S2). CFZ-NH+ are stacked in a head-to-tail fashion. This 
arrangement is further stabilized by weak C-H⋯O H-bonds (Table S2). Powder pattern of the as 
synthesized product matches the one calculated from single-crystal data (Figure S1). 
Acta Crystallographica Section B    research papers 
15 
 
 
Figure 4  MeOH molecules serve as bridges between 2,4-DHBA- in the structure of CFZ-NH+-
2,4DHBA--MeOH (1:1:1). 
3.3.6. CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) nonstoichiometrically solvated cocrystal 
of salt. 
Clofaziminium terephthalate terephthalic acid nonstoichiometrically solvated cocrystal of salt 
crystallizes in 𝑃1ത space group (Table 3). Its asymmetric unit is composed of one ion of clofaziminium 
with a half terephthalate ion and a half molecule of terephthalic acid (Figure 3 (f)). Indeed, terephtalic 
acid and terephthalate are both positioned on an inversion center. Proton transfer between 
terephthalate (O1) and the isopropyl imine of CFZ (N4) occurs and is confirmed by an increase of the 
iminium angle (Table S3). Actually, terephthalate anion serves as a linker between two clofaziminium 
cations, generating three-component CFZ-NH+-TRPTA2--CFZ-NH+ assemblies (Figure 5 (a)). In 
those, a 𝑅ଶଵ(7) H-bond motif is observed between TRPTA2- and CFZ-NH+ (N4+-H⋯O1- and N3-
H⋯O1-) (Table S2). Those three-component assemblies are interconnected through H-bonds between 
terephthalate anions and terephthalic acid molecules (𝐷ଵଵ(2) H-bond motif, O1A-H⋯O1-) (Figure 5 
(a) and Table S2). Weak C-H⋯O bonds are also present in the structure (Table S2). This arrangement 
results in solvent accessible voids forming channels (Figure 5 (b) and S4(a)). Although one molecule 
of ethyl acetate could be localized, high residual electron densities remained in the structure. As all 
crystallization solvent molecules could not be assigned unambiguously despite low temperature 
measurement (100K), Platon Squeeze (Spek, 2015) procedure was applied to the data.  
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Figure 5 Three-component assemblies (capped stick) linked by terephthalic acid (ball and stick) of 
CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) (a) and of CFZ-NH+-TRPTA2--TRPTA 
(1:0.5:0.5) (c). Voids along b-axis (top) and c-axis (bottom) of CFZ-NH+-TRPTA2--TRPTA-solvent 
(1:0.5:0.5:x)  (b) and of CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5) (d). 
3.3.7. CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5) cocrystal of salt.  
Clofaziminium terephthalate terephthalic acid cocrystal of salt (Figure 3 (g)) was obtained by drying 
CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) at room temperature. CFZ-NH+-TRPTA2--
TRPTA (1:0.5:0.5) cocrystal of salt crystallizes in 𝑃1ത space group (Table 3). Its asymmetric unit is 
composed of one ion of clofaziminium with a half terephthalate ion and a half molecule of 
terephthalic acid (Figure 3 (f)). Indeed, terephtalic acid and terephthalate are both positioned on an 
inversion center. Proton transfer between terephthalate (O1) and the isopropyl imine of CFZ (N4) 
occurs and is confirmed by an increase of the iminium angle (Table S3). Like in the solvated 
structure, terephthalate anion serves as a linker between two clofaziminium cations, leading to three-
component assemblies. Bifurcated H-bonds between TRPTA2- and CFZ-NH+ are observed (𝑅ଶଶ(9) 
motif, N4-H+⋯O1- and N3-H⋯O2-) in addition to the 𝑅ଶଵ(7), N4+-H⋯O1- and N3-H⋯O1- (Table S2). 
Three-component assemblies are interconnected through H-bonds with terephthalic acid molecules 
(𝐷ଵଵ(2) H-bond motif, O1B-H⋯O2-) (Figure 5 (c)) (Table S2). Voids are present in the structure of 
CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5), however, they are not interconnected and no channel is 
observed (Figure 5 (d) and S4(b)). Interestingly, as shown by variable temperature powder X-ray 
diffraction, this non-solvated structure can be obtained by heating the batch powder synthesized by 
LAG with EtOAc as solvent (Figure S3). 
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3.4. CFZ-counter ion interaction comparison. 
Full interaction map analyses revealed two possible sites of interaction around clofazimine, namely, 
near nitrogen atoms N3 and N4 for the first site and around N2 for the second one. Analysis of the 18 
known structures (15 on CSD and 3 supplied as supplementary data from the article of Bannigan et al. 
(Bannigan et al., 2017)) and the seven new ones described in this paper reveals that first site is 
implied in all salt structures while the second one is only implied in two structures. One structure is 
the hydrated salt CFZ-NH+-MSA--H2O (1:1:1). Indeed, N2 interacts through H-bonds with a water 
molecule (𝐷ଵଵ(2), 2.899(4) Å and 173(2)°) (Figure 6 (a)). In this case, the water molecule is placed at 
an optimal position (even for a contour level as high as 30). The second structure is CFZ-NH+-CIT- 
(1:1) in which N2 interacts through H-bond  with one carboxylic group of dihydrogen citrate ion 
(𝐷ଵଵ(2), 2.898(4) Å and 161.6°, Figure 6 (b)). In this structure, the OH from the carboxylic acid 
interacting with N2 is, however, less optimally placed. While H-bonds between N2 from CFZ and OH 
from 2,4-DHBA or MeOH could have been expected, such interaction is not observed in the structure 
of CFZ-NH+-2,4DHBA--MeOH (1:1:1). 
 
Figure 6 FIMs calculated around clofaziminium from CFZ-NH+-MSA--H2O (1:1:1) (a) and CFZ-
NH+ of CFZ-NH+-CIT- (1:1) (b) carbonyl oxygen, uncharged NH and alcohol OH probes in red, blue 
and orange respectively. 
Concerning clofaziminium salts obtained with aliphatic dicarboxylic acids, in currently known 
structures, proton transfer occurred from one carboxylic acid function, while the other remained 
protonated. However, in the structures involving the aromatic dicarboxylic acid CFZ-NH+-TRPTA2--
TRPTA (1:0.5:0.5) and CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x)), terephthalate anion is 
fully unprotonated, leading to three component assemblies (CFZ-NH+-TRPTA2--CFZ-NH+) bridged 
together by the remaining terephthalic acid molecule (CFZ and TRPTA were ball milled in 1/1 molar 
ratio). Double deprotonation of terephthalic acid could eventually be explained by the two low pKa 
values for this compound (3.54 and 4.34). But interestingly, fumaric acid, which has second pKa 
value similar to the one of terephthalic acid (pKa of 3.02 and 4.38 for FA) is unprotonated at only one 
site, forming thus hydrogen fumarate salt of clofazimine. This observation could be explained by the 
longer distance between carboxylates in TRPTA in comparison with the COOH-COOH distance in 
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FA (5.803(3) in the structure of CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5) vs. 3.883(3) in the structure 
of CFZ-NH+-FA- (1:1)). 
3.5. Crystal packing comparison 
All known clofaziminium salt structures, as well as those described in this paper, were compared by 
submitting them to the crystal packing similarity tool in CCDC Mercury (Macrae et al., 2008) with a 
packing shell size of 15 molecules and a distance and angle tolerance of 30% and 30° respectively. 
Only CFZ-NH+-SA- (1:1) showed a molecular overlay of 15 molecules out of 15 with CFZ-NH+-
MLN- (1:1) (GESGOC). This result was quite interesting. Indeed, isostructurality could have been 
expected between salts implying hydrogen succinate and hydrogen fumarate as counter-ion (as were 
previously described by J.Galcera et al.) (Galcera & Molins, 2009). However, crystal packing 
comparison of clofaziminium salts CFZ-NH+-FA- (1:1) and CFZ-NH+-SA- (1:1) indicates a lack of 
isostructurality. The negative charge on the carboxylate part of hemisuccinate favors the formation of 
a strong intramolecular H-bond at the expense of intermolecular H-bonds (in contrast to the one 
observed in CFZ-NH+-FA- (1:1)) preventing isostructurality with CFZ-NH+-FA- (1:1). This 
intramolecular H-bond could be similar to the one observed in hydrogen maleate in the structure of 
CFZ-NH+-MLE- (1:1), described by G. Bolla and A. Nangia (Bolla & Nangia, 2012). However, no 
isostructurality is observed with CFZ-NH+-MLE- (1:1).  
 
Figure 7 Structure of salt CFZ-NH+-SA- (1:1)1 (a), of overlay between CFZ-NH+-SA- (1:1) and 
CFZ-NH+-MLN- (1:1) (b), and of CFZ-NH+-MLN- (1:1) (c). Crystal packing comparison of CFZ-
NH+-SA- (1:1) (green) with CFZ-NH+-MLN- (1:1) salt (grey) (d). 
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More surprisingly, CFZ-NH+-SA- (1:1) presents isostructurality with CFZ-NH+-MLN- (1:1), a 
clofaziminium salt previously described by G. Bolla and A. Nangia (Bolla & Nangia, 2012). The 
overlay between the crystal lattice of CFZ-NH+-SA- (1:1) and the one of CFZ-NH+-MLN- (1:1) is 
illustrated in Figure 7. Other crystal packings that are interesting to compare are those of CFZ-NH+-
SACC—MeCN (1:1:1.4) and of CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) with their non-
solvated analogues (CFZ-NH+-SACC- (1:1) and CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5)). In terms 
of composition, those salts differ only by the presence or absence of solvent in the structure. However, 
this solvent may have a strong impact on the crystal packing.Indeed in the non-solvated structure of 
CFZ-NH+-SACC-, a  𝑅ଶଵ(7) H-bond motif is observed between SACC- and CFZ-NH+ (N4+-H⋯N5- 
and N3-H⋯N5-) while in the solvated salt a 𝑅ଶଶ(9) motif (N4+-H⋯O3 and N3-H⋯N5-) is observed. 
Such modification of H-bond results in a slight shift in the position of SACC- (Figure 8). However 
both structures are quite similar as 14 clofaziminium ions over 15 overlay when solvated and non-
solvated structures are analysed by the crystal packing similarity tool in CCDC mercury (Macrae et 
al., 2008). More structural changes are observed between CFZ-NH+-TRPTA2--TRPTA-solvent 
(1:0.5:0.5:x) and CFZ-NH+-TRPTA2--TRPTA- (1:0.5:0.5) (Figure 9 (c)). In the non-solvated 
structure, H-bonds observed between TRPTA2- and CFZ-NH+ are bifurcated, which is not the case in 
its solvated analog. Those bifurcated H-bonds lead to major modifications in terms of distance 
between the planes passing through the main core of CFZ-NH+ (those planes were calculated by 
taking N1, C5 and C6 atoms of clofaziminium as reference). Indeed, while the inter-plane distance is 
6.049Å in the structure of CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) (d, Figure 9 (a)), it is 
only 2.217 Å in the one of CFZ- NH+-TRPTA2--TRPTA (1:0.5:0.5) (d, Figure 9(b)). The differences 
in crystal packing observed between those two structures result in major changes in terms of (solvent 
accessible) voids. Indeed in the structure of CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x), 
solvent accessible voids form channels as illustrated at Figure 5 (b) while in that of CFZ-NH+-
TRPTA2--TRPTA (1:0.5:0.5) voids are not interconnected and no channel is observed (Figure 5 (d)). 
 
Figure 8  Crystal packing overlay of solvated (green) and non-solvated structures of clofaziminium 
saccharinate. 
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Figure 9 Distance, d, between the planes passing through the main core of CFZ-NH+ in the 
structures of CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x)  (a) and CFZ-NH+-TRPTA2--
TRPTA (1:0.5:0.5) (b). Crystal packing overlay of solvated (green) and non-solvated structures (c). 
3.6. Conformational analysis of clofazimine/clofaziminium.  
Clofazimine/clofaziminium conformation is quite restrained, however, conformational 
changes could be expected around three main torsion angles (T1, T2 and T5 Figure 1) for 
clofazimine and around four torsion angles for clofaziminium (T1, T2, T4 and T5 Figure 1). 
T3 torsion angle (Figure 1) is however expected to have values around 90° (because of steric 
hindrance that would result from T3 torsion angles values different from 90°). To assess the 
conformational versatility of clofazimine(ium), coordinates were extracted from known 
structures (from CSD data, and supplementary data from the article of Bannigan et al. 
(Bannigan et al., 2017)) and overlaid (Figure 10 (a) and (b)). Results indicate similar 
conformations of all clofazimine molecules (Figure 10 (a)) which could be explained by the 
formation of an intramolecular H-bond between N3-H and N4. Main differences are observed 
around T1 and T2 torsion angles. T1 and T2 have values around 150 or -150° with two possible 
combinations: for negative T2 values, T1 can be either positive (CFZ I and II), or negative (Table S3).  
Clofaziminium ions also adopt similar conformations (Figure 10 (b)). T1 torsion angle is quite well 
conserved in salts structures with main values being comprised between 130 and 160°. 
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Figure 10 Front and side views after superimposition of clofazimine (a) and clofaziminium (b) 
conformations, optimized geometries of clofazimine (c), of clofaziminium without any counter-ion (d)  
and of clofaziminium with Cl- counter-ion (e). 
However, flexibility is observed around T2. Indeed, T2 torsion angle can adopt different values 
around 150-160°, 90-100°, and 70-80°. More surprising are the values of T4 and T5 torsion angles. 
Indeed T4 torsion angles are comprised between 0 and 15° while T5 values are mainly comprised 
between 0 and 20° in absolute value (there are few exceptions: 38° in CFZ-NH+-SACC--MeCN 
(1:1:1.4), 31° in CFZ-NH+-SACC-(1:1) -28° and 34° in CFZ-NH+-TRPTA2--TRPTA-solvent 
(1:0.5:0.5:x) and CFZ-NH+-FA- (1:1)). Such values of T4 and T5 result in steric hindrance between 
the hydrogen atoms positioned on N3 and N4 (distance around those hydrogen atoms is around 1.9 Å 
(Table S3)). Because of this steric effect, other values of T4 and T5 could be expected, indeed N3-H 
could be tilted outside the plane of clofazimine. To assess the effect of the counter-ion on CFZ-NH+ 
conformation, optimization calculations were performed in absence and in presence of the counter-ion 
(Cl-), starting from coordinates of clofaziminium chloride (LABQUD) (Figure 9 (d) and (e) and table 
S5 and S6). Optimization of clofazimine was also performed (starting from coordinates of 
DAKXUI03) (Figure 10 (c) and Table S4) for the sake of comparison. Optimized CFZ-NH+ 
conformation confirms the hypothesis of possible higher T5 torsion angle values (T4 = 15.40° and 
T5= 51.35°). Such a high value of T5 is however never observed in crystal structures. This suggests a 
quite strong effect of the counter-ion on clofaziminium conformation. Indeed, in clofaziminium salt 
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crystal structures, the hydrogen atom positioned on N3 remains almost in the plane of clofazimine. 
This could be explained by the presence of H-bonds between CFZ-NH+ and its counter-ion, which 
forces the N3-H to stay close to the clofaziminium plane and compensates for the energy penalty due 
to steric hindrance. This assumption is supported by the fact that the optimized geometry of CFZ-NH+ 
in presence of Cl- counter-ion results in T5 torsion values much closer, in absolute value, to the ones 
observed in crystal structures (T4=-3.41° and T5=-11.34° in optimized CFZ-NH+-Cl- (1:1)) (Figure 
10 (e) compared to Figure 10 (b) and Table S3). 
4. Conclusions 
Six new (solvated/cocrystal of) salts of clofazimine drug with fumaric, succinic, 2,4-
dihydroxybenzoic and terephthalic acids as well as with saccharin are reported and compared to the 
currently known clofaziminium salt structures. While full interaction map analyses reveal two main 
sites of interaction around clofaziminium, CFZ-NH+ interaction with its counter-ion mainly occurs at 
the site located around N3 and N4. Interaction at the second site of clofaziminium is only observed in 
two structures (CFZ-NH+-CIT- (1:1) and CFZ-NH+-MSA--H2O (1:1:1)) that were already reported. 
Acid/base reaction between clofazimine and dicarboxylic acids, more often results in single proton 
transfer (one carboxylic acid function is unprotonated while the other remains protonated) except in 
the structures implying terephthalic acid (in which COOH-COOH distance is longer than in aliphatic 
dicarboxylic acids evaluated in the present work). In structures implying terephthalic acid, one 
terephthalate ion is fully unprotonated while the remaining terephthalic acid molecules serve as 
bridges between terephthalate anions. Crystal packing comparison of all known structures revealed 
that CFZ-NH+-SA- (1:1) and CFZ-NH+-MLE- (1:1) are isostructural. CFZ-NH+-SACC--MeCN 
(1:1:1.4) and CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) can be converted to CFZ-NH+-
SACC- (1:1) and CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5)  by solvent evaporation. In both case 
solvent evaporation leads to structural changes and in H-bond interactions. Crystal packing 
comparison of those two structures reveals that in clofaziminium saccharinate, anion position is 
slightly changed while in clofaziminium terephthalate, solvent has a strong impact on H-bond 
interactions and packing. Indeed, H-bond interactions between CFZ-NH+ and TRPTA2- change upon 
drying, leading to the disappearance of solvent accessible channels in favor of isolated voids. In all 
known structures, clofazimine and clofaziminium adopt similar conformations. The one observed in 
salt structures may be surprising at first glance because it results in steric hindrance around the 
protonated site. However conformational optimization of clofaziminium showed the strong impact of 
the counter-ion on CFZ-NH+ conformation. Indeed, H-bonds occurring between clofaziminium and 
the counter-ion compensate the energy penalty due to the steric hindrance. Altogether, these results 
indicate that despite its quite restrained conformation, clofazimine can crystallize as salts with a high 
variety of packing, which could lead to different physicochemical and pharmacokinetic properties. 
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 List of Figure and Table captions: 
Figure 1: (a) Numbering scheme of clofazimine/ium(CFZ/CFZ-NH+) (torsions angles: T1, C8-N3-
C19-C20; T2, C9-N4-C25-C27; T3, C12-N1-C13-C18 T4, H-N4-C9-C8 and T5, H-N3-C8-C9) and 
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selected acids in the present work : fumaric acid, succinic acid, DL-malic acid, 2,4-dihydroxybenzoic 
acid, saccharin, L-aspartic acid, terephthalic acid and citric acid. (b) Acids crystallized with 
clofazimine by G. Bolla et al. (Bolla & Nangia, 2012) and (c) acids crystallized with clofazimine by 
P. Bannigan et al. (Bannigan et al., 2017). CFZ-NH+-CIT- (1:1) salt was already described by P. 
Bannigan et al. (Bannigan et al., 2017), in the present study salt formation of CFZ/CIT in 2/1 and 3/1 
molar ratios was attempted. 
 
Figure 2: FIMs calculated around clofazimine (a) and clofaziminium  (b). Carbonyl oxygen, 
uncharged NH and alcohol OH probes in red, blue and orange respectively. 
Figure 3: H-bond interactions in the structures of CFZ-NH+-FA- (1:1) (a), CFZ-NH+-SA- (1:1) (b), 
CFZ-NH+-SACC--MeCN (1:1:1.4) (c), CFZ-NH+-SACC- (1:1)- (d) CFZ-NH+-2,4DHBA--MeOH 
(1:1:1) (e), CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) (f) and CFZ-NH+-TRPTA2--TRPTA 
(1:0.5:0.5) (g). Ellipsoids are drawn at the 50% probability level. 
Figure 4: MeOH molecules serve as bridges between 2,4-DHBA- in the structure of CFZ-NH+-
2,4DHBA--MeOH (1:1:1). 
Figure 5: Three-component assemblies (capped stick) linked by terephthalic acid (ball and stick) of 
CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) (a) and of CFZ-NH+-TRPTA2--TRPTA 
(1:0.5:0.5) (c). Voids along b-axis (top) and c-axis (bottom) of CFZ-NH+-TRPTA2--TRPTA-solvent 
(1:0.5:0.5:x) (b) and of CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5) (d).  
Figure 6: FIMs calculated around clofaziminium from CFZ-NH+-MSA--H2O (1:1:1) (a) and CFZ-
NH+ of CFZ-NH+-CIT- (1:1) (b) carbonyl oxygen, uncharged NH and alcohol OH probes in red, blue 
and orange respectively. 
Figure 7: Structure of salt CFZ-NH+-SA- (1:1) (a), of overlay between CFZ-NH+-SA- (1:1) and 
CFZ-NH+-MLN- (1:1) (b), and of CFZ-NH+-MLN- (1:1) (c). Crystal packing comparison of CFZ-
NH+-SA- (1:1) (green) with CFZ-NH+-MLN- (1:1) salt (grey) (d). 
Figure 8: Crystal packing overlay of solvated (green) and non-solvated structures of clofaziminium 
saccharinate. 
 
Figure 9: Distance, d, between the planes passing through the main core of CFZ-NH+ in the 
structures of CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) (a) and CFZ-NH+-TRPTA2--
TRPTA (1:0.5:0.5) (b). Crystal packing overlay of solvated (green) and non-solvated structures (c). 
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Figure 10: Front and side views after superimposition of clofazimine (a) and clofaziminium (b) 
conformations, optimized geometries of clofazimine (c), of clofaziminium without any counter-ion (d)  
and of clofaziminium with Cl- counter-ion (e). 
Table 1: Clofazimine salification assays and corresponding results. 
Table 2: Melting points of non-solvated clofaziminium salts. 
Table 3:  Experimental details. 
Table S1: Published and new structures implying clofazimine or clofaziminium. 
Table S2: Selected hydrogen-bond parameters. 
Table S3: T1, T2, T3, T4, and T5 torsions angles, C9-N4-C25 angle, and H-H distance between N3-
H and N4-H in clofazimine/clofaziminium in published and new structures as well as in optimized 
structures. Data from structures presented in this work are written in italic. A, B, C and D annotations 
indicate different molecules in the asymmetric unit while 1 and 2 superscripts indicate the two 
positions observed in case of disorder. NA means that hydrogen is not present in cif file. 
Table S4: Atomic coordinates of optimized clofazimine (DAKXUI03). 
Table S5: Atomic coordinates of optimized geometry of clofaziminium without any counter-ion. 
Table S6: Atomic coordinates of optimized geometry of clofaziminium with Cl- counter-ion 
(LABQUD). 
Figure S1: Powder patterns of (a), from bottom to top, CFZ, FA, CFZ/FA LAG MeCN batch powder 
and  CFZ-NH+FA- (1:1) calculated pattern from SCXRD data, (b)  CFZ, SA, CFZ/SA LAG MeCN 
batch powder and CFZ-NH+-SA- (1:1) calculated pattern from SCXRD data, (c) CFZ, SACC, 
CFZ/SACC LAG MeCN batch powder and  CFZ-NH+-SACC- (1:1) and CFZ-NH+-SACC--MeCN 
(1:1:1.4) calculated patterns from SCXRD data, (d) CFZ, 2,4-DHBA, CFZ/2,4-DHBA LAG MeOH 
batch powder and CFZ-NH+-2,4DHBA--MeOH (1:1:1) calculated pattern from SCXRD data 
Figure S2: Powder patterns of: (a), CFZ, DL-MAL and CFZ/DL-MAL LAG MeCN batch powder, 
(b) CFZ, L-ASP, CFZ/L-ASP LAG MeCN batch powder, (c) CFZ, TRPTA, CFZ/TRPTA LAG 
EtOAc, CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) calculated pattern from SCXRD data, 
CFZ/TRPTA LAG EtOAc batch powder at 25°C after heating to 200°C and CFZ-NH+-TRPTA2--
TRPTA (1:0.5:0.5) calculated from SCXRD data, (d) CFZ, CIT, CFZ-NH+-CIT- (1:1) calculated 
from SCXRD data (Bannigan et al., 2017), CFZ/CIT 2/1 LAG MeOH/MeCN 50/50, CFZ-CIT 2/1 
calculated from SCXRD data obtained at 100K (structure intrinsically disordered) and CFZ/CIT 3/1 
LAG MeOH/MeCN 50/50. * SCXRD data from cif file available in the publication of Bannigan et al. 
(Bannigan et al., 2017). 
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Figure S3: (a)Variable temperature powder X-ray diffraction of CFZ/TRPTA LAG EtOAc batch 
powder and comparison with calculated pattern of CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5). 
Desolvatation of a solvated crystalline powder occurred to give a non-solvated crystalline powder 
matching the calculated powder pattern of CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5). (b) Zoom on the 
5-15° 2𝜃 region, disappearing peak upon heating at 2𝜃 value of 7.7° highlighted by plain line frame, 
appearing peaks upon heating at 2𝜃 values of 8.8 and 9.2° (dashed frame) as well as 11.5 and 12.0° 
(dotted frame). 
Figure S4: Channel arrangement and solvent accessible voids in the structure of CFZ-NH+-TRPTA2-
-TRPTA-solvent (1:0.5:0.5:x) (view along  a-axis) (a)  and in the one of CFZ-NH+-TRPTA2--
TRPTA (1:0.5:0.5) (view along  a-axis) (b). 
Figure S5: Effect of different solvents while grinding (a) CFZ with FA, (b) CFZ with SA, (c) CFZ 
with SACC.  
Figure S6: Effect of different solvents while grinding (a) CFZ with TRPTA, (b) CFZ with CIT in 1/1 
molar ratio, (c) CFZ with CIT in 2/1 molar ratio and (d) CFZ with CIT in 3/1 molar ratio. 
Figure S7: Hirshfeld surface analysis (red regions highlighting close contacts), 2D-fingerprint plots 
(based on the surface generated on the molecules/ions present in the asymmetric unit) and percentage 
contribution to the Hirshfeld surface area for the different close contacts in the structures of (a) CFZ-
NH+-FA- (1:1) (b) CFZ-NH+-SA- (1:1), (c) CFZ-NH+-SACC--MeCN (1:1:1.4), (d) CFZ-NH+-
SACC-(1:1), (e) CFZ-NH+-2,4DHBA--MeOH (1:1:1) and (f) CFZ-NH+-TRPTA2--TRPTA 
(1:0.5:0.5).  
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Supporting information  
Table S1 Published and new structures implying clofazimine or clofaziminium.  
Structure Space Group a, b, c (Å); 𝛼, 𝛽, 𝛾 (°);  V (Å³) Z CSD refcode reference 
CFZ (I) 𝑃1ത 10.10.507(4), 12.852(12), 9.601(2); 95.95(4), 97.22(1), 69.73(6); 1204.0(13) 2 DAKXUI01 
(Bannigan et al., 
2016) 
CFZ (II) 𝑃2ଵ/𝑎 
7.788(14), 22.960(13), 13.362(7); 90, 98.58(12), 
90; 2363(5) 4 DAKXUI 
(Bannigan et al., 
2016) 
CFZ (III) 𝑃𝑏𝑐𝑎 23.2417(15), 8.1118(5), 25.5891(16); 90, 90, 90; 4824.4(5) 8 DAKXUI03 
(Bannigan et al., 
2016) 
CFZ (IV) 𝑃2ଵ/𝑐 
12.9083, 23.3031, 8.3092; 90, 95.1697, 90; 
2489.27 4 DAKXUI02 
(Bannigan et al., 
2016) 
CFZ-DMF 𝑃1ത 12.435(4), 12.807(5), 10.424(4); 111.74(3), 112.37(3), 90.90(3); 1402.0(10) 2 CEKTER 
(Eggleston et al., 
1984) 
CFZ-(CH3)2CO (1:1) 𝑃1ത 
10.0842(13), 12.0695(16), 12.6613(16); 75.278(2), 
66.588(2), 69.051(2); 1309.3(3) 2 GESHIX 
(Bolla & Nangia, 
2012) 
CFZ-NH+-H2PO4--H2O 
(1:1:0.25)  𝑃1
ത 14.3064 (9), 15.1345 (9), 27.9096 (17); 96.495 (2), 92.025 (2), 110.640 (2); 5600.4(6) 8 - 
(Bannigan et al., 
2017) 
CFZ-NH+-HSO4--MeOH (1:1:1) 𝐶2/𝑐 
18.9579(11), 15.4754(9), 20.0404(12); 90, 
100.360(2), 90; 5783.6(6) 8 - 
(Bannigan et al., 
2017) 
CFZ-NH+-MSA--H2O (1:1:1) 𝑃1ത 
9.5945(12), 11.0456(12), 14.4628(11); 110.173(9), 
95.859(9), 94.929(9); 1419.1(3) 2 GESHET 
(Bolla & Nangia, 
2012) 
CFZ-NH+-2,4DHBA--MeOH 
(1:1:1) 𝑃1
ത 9.4861(4), 12.5322(5), 15.3641(5); 98.415(3), 103.379(3), 110.450(4); 1612.40(11) 2 / This work  
CFZ-NH+-SACC--MeCN 
(1:1:1.4) 𝑃1
ത 7.9970(3), 13.5824(3), 16.6638(7); 80.214(3), 80.034(4), 83.036(3); 1748.87(11) 2 / This work 
CFZ-NH+-TRPTA2--TRPTA-
solvent (1:0.5:0.5:x) 
𝑃1ത 11.7990(4), 12.0736(4), 14.6803(5); 72.472(3), 80.688(3), 72.030(3); 1891.44(12) 2 / This work 
CFZ-NH+-Cl--H2O (1:1:0.13) 𝑃𝑏𝑐𝑎 
10.2664(4), 19.8275(7), 24.1558(9); 90, 90, 90; 
4917.1(3) 8 RAFHUE 
(Horstman et al., 
2017) 
CFZ-NH+-Cl- (1:1) 𝑃𝑏𝑐𝑎 
10.74739(15), 19.1763(4), 24.2362(3); 90, 90, 90; 
4994.96(14) 8 LABQUD 
(Keswani et al., 
2015) 
CFZ-NH+-MSA- (1:1) 𝑃2ଵ/𝑛 
10.0229 (18), 17.772 (3), 15.592 (3); 90, 103.028 
(4), 90; 2705.9(8) 4 GESGAO 
(Bolla & Nangia, 
2012) 
CFZ-NH+-MLE- (1:1) 𝑃2ଵ/𝑛 
11.2549(19), 20.816(3), 12.519(2); 90, 
103.413(17), 90; 2853.0(8) 4 GESHAP 
(Bolla & Nangia, 
2012) 
CFZ-NH+-INA- (1:1) 𝑃1ത 
9.8153(9), 12.1738(10), 15.2122(10); 72.455(7), 
77.844(7), 66.479(8); 1580.7(2) 2 GESGES 
(Bolla & Nangia, 
2012) 
CFZ-NH+-NA- (1:1) 𝑃1ത 
11.6032(13), 15.361(2), 18.733(3); 111.337(14), 
91.280(11), 109.295(11); 2896.5(8) 4 GESGIW 
(Bolla & Nangia, 
2012) 
CFZ-NH+-MLN- (1:1) 𝑃1ത 9.8401(8), 12.4069(10), 13.0576(10); 74.129(1), 70.300(1), 67.520(1); 1367.50(19) 2 GESGOC 
(Bolla & Nangia, 
2012) 
CFZ-NH+-SCL- (1:1) 𝑃1ത 
10.8702(6), 11.2066(6), 13.8272(8); 82.354(5), 
88.960(5), 63.492(6); 1492.31(17) 2 GESGUI 
(Bolla & Nangia, 
2012) 
CFZ-NH+-CIT- (1:1) 𝑃1ത 
14.7409(6), 15.8211(6), 16.2514(7); 71.928(1), 
63.041(1), 70.747(2); 3130.6(2) 4 - 
(Bannigan et al., 
2017) 
CFZ-NH+-TRPTA2--TRPTA 
(1:0.5:0.5) 𝑃1
ത 10.4028 (3), 10.8454 (3), 15.4229 (5); 71.183 (3), 73.984 (3), 76.148 (2); 1561.33 (9) 2 / This work 
CFZ-NH+-SACC- (1:1) 𝑃1ത 8.2115 (7), 13.5327 (12), 14.325 (3); 89.04 (1), 88.864 (10), 83.781 (7) 2 / This work 
CFZ-NH+-FA- (1:1) 𝑃2ଵ/𝑐 
7.47882(9), 26.0041(3), 14.78241(16); 90, 
102.5075(12), 90; 2806.65(6) 4 / this work 
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CFZ-NH+-SA- (1:1) 𝑃1ത 
10.6455(6), 12.2850(5), 12.8049(8); 90.076 4), 
113.218(6), 108.289(4); 1446.18(15) 2 / this work 
Table S2 Selected hydrogen-bond parameters. 
D—H···A D—H (Å) H···A (Å) D···A (Å) D—H···A (°) 
CFZ-NH+-FA- (1:1) 
N3—H3···O2 0.83 (3) 2.48 (3) 3.003 (3) 122 (2) 
N3—H3···O3- 0.83 (3) 2.26 (3) 3.040 (3) 156 (3) 
N4+—H4···O3- 0.84 (3) 2.17 (3) 2.972 (2) 160 (2) 
O1—H1A···O3-  0.94 (4) 1.62 (4) 2.550 (2) 176 (3) 
CFZ-NH+-SA- (1:1) 
N4+—H4···O1-  0.85 (3) 1.98 (3) 2.824 (3) 170 (2) 
N3—H3···O1- 0.83 (3) 2.11 (2) 2.871 (3) 152 (3) 
O4—H4B···O2- 0.94 (3) 1.56 (3) 2.497 (3) 177 (3) 
C15—H15···O1-  0.93 2.31 3.233 (3) 174.6 
C29B—H29D···Cl2 0.97 2.80 3.416 (14) 122.2 
CFZ-NH+-SACC- (1:1) 
N4+—H4···N5- 0.79 (7) 2.22 (8) 2.99 (2) 163 (8) 
N4+—H4···N5A- 0.79 (7) 2.25 (8) 3.04 (2) 174 (8) 
N3—H3···N5- 1.05 (7) 1.78 (7) 2.84 (2) 178 (5) 
N3—H3···N5A- 1.05 (7) 1.88 (7) 2.92 (2) 165 (5) 
C24—H24···O1 0.93 2.48 3.40 (2) 167.9 
C26—H26C···O2 0.96 2.55 3.49 (2) 166.1 
C26—H26C···O2A 0.96 2.45 3.370 (18) 160.9 
CFZ-NH+-SACC--MeCN (1:1:1.4) 
N3—H3···N5- 0.87(3) 2.03(3) 2.893(3) 170(3) 
N4+—H4N···O3 0.85(4) 2.45(4) 3.264(3) 160(3) 
C33—H33···O3 0.95 2.45 3.283(3) 146.0 
C24—H24···O1 0.95 2.42 3.314(3) 157.3 
CFZ-NH+-2,4DHBA--MeOH (1:1:1) 
N4+—H4N···O1A- 0.853 (19) 2.00 (2) 2.852 (10) 174.9 (17) 
N4+—H4N···O1B- 0.853 (19) 2.00 (3) 2.854 (18) 176.2 (18) 
N3—H3N···O1A- 0.89 (2) 1.88 (3) 2.743 (13) 164 (2) 
N3—H3N···O1B- 0.89 (2) 1.86 (3) 2.73 (2) 169 (2) 
O3A—H3OA···O2A- 1.02 1.66 2.556 (15) 144.5 
O4A—H4OA···O5A 0.82 2.02 2.786 (10) 155.2 
O5A—H5OA···O3A 0.82 2.39 3.192 (12) 166.6 
O3B—H3OB···O2B- 1.02 1.42 2.33 (3) 146.4 
O4B— H4OB···O5B 0.82 2.10 2.86 (2) 154.5 
O5B—H5OB···O4B 0.82 2.17 2.64 (2) 116.1 
C14—H14···O1A- 0.93 2.45 3.346 (11) 161.4 
C14—H14···O1B- 0.93 2.57 3.467 (19) 162.1 
C23—H23···O4A 0.93 2.50 3.207 (8) 132.8 
C23—H23···O4B 0.93 2.41 3.204 (16) 143.3 
CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) 
N4+—H4···O1- 0.841 (16) 2.071 (16) 2.8985 (13) 167.7 (15) 
N3—H3···O1- 0.866 (18) 1.947 (18) 2.7772 (14) 160.1 (16) 
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O1A—H3B···O1- 0.91 (2) 1.64 (2) 2.5442 (13) 171 (2) 
C15—H15···O2- 0.95 2.44 3.3792 (17) 170.8 
CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5) 
N4+—H4···O1- 0.86 (2) 1.98 (2) 2.8363 (19) 172.9 (18) 
N3—H3···O2- 0.85 (2) 2.17 (2) 2.976 (2) 159 (2) 
N3—H3···O1- 0.85 (2) 2.30 (2) 2.996 (2) 140 (2) 
O1B—H3B···O2- 0.95 (3) 1.66 (3) 2.5936 (19) 170 (3) 
C14—H14···O1- 0.93 2.40 3.276 (2) 156.7 
C20—H20···O2- 0.93 2.54 3.307 (2) 139.7 
C26—H26C···O2B 0.96 2.55 3.502 (3) 171.5 
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Table S3 T1, T2, T3, T4, and T5 torsions angles, C9-N4-C25 angle, and H-H distance between 
N3-H and N4-H in clofazimine/clofaziminium in published and new structures as well as in optimized 
structures. Data from structures presented in this work are written in italic. A, B, C and D annotations 
indicate different molecules in the asymmetric unit while 1 and 2 superscripts indicate the two 
positions observed in case of disorder. NA means that hydrogen is not present in cif file. 
Structure 
T1 (°) 
(C8-N3-C19-
C20) 
T2 (°) 
(C9-N4-C25-
C27) 
T3 (°) 
(C12-N1-
C13-C18)  
T4 (°) 
(H-N4-
C9-C8) 
T5 (°) 
(H-N3-
C8-C9) 
Angle 
C9-N4-C25 
(°) 
H-H distance 
between N3-
H and N4-H 
CFZ (I) 154.9(7) -154.8(8) 92.1(8) / -9.9 119.2(5) / 
CFZ (II) 149.4(3) -157.1(3) 82.1(3) / -13(2) 120.7(2) / 
CFZ (III) -163.1(3) -152.5(2) 87.8(3) / 9.6(4) 120.4(2) / 
CFZ (IV) -146.83 -99.94 110.71 / 0.72 120.71 / 
CFZ-DMF -149.90 -138.45 99.44 / NA 118.18 / 
CFZ-(CH3)2CO (1:1) -146.4(2) -159.5(2) 97.0(2) / 5.1 119.2(2) / 
CFZ-NH+-H2PO4--H2O 
(1:1:0.25) 
A: 133.8(5)  
B:-133.6(5) 
C: 135.2(6) 
D: 130.7(5) 
A: -78.2(5) 
B: -156.3(4) 
C: -95.9(6) 
D: -76.3(7) 
A: 63.6(5) 
B: 93.3(5) 
C: 82.9(7) 
D: 91.1(7) 
A:-14.4 
B: -2.1 
C: 1.1 
D:-11.3 
A: 2.4 
B: -1.9 
C: -2.1 
D: 3.9 
A: 125.3(3) 
B: 124.1(4) 
C: 127.6(5) 
D: 125.8(4) 
A: 1.8565 
B: 1.7934 
C: 1.7794 
D: 1.8702 
CFZ-NH+-HSO4--MeOH 
(1:1:1) 143.4(2) -78.8(3) 81.1(3) 1.3 -14.2 124.7(2) 1.8226 
CFZ-NH+-MSA--H2O 
(1:1:1) 174.9(2) -154.3(3) 95.0(3) -12(2) -10.(2) 125.2(2) 1.83(4) 
CFZ-NH+-2,4DHBA--
MeOH (1:1:1) -142.18(15) -169.69(14) 106.25(15) -1(1) 13(2) 126.25(13) 1.83(3) 
CFZ-NH+-SACC--MeCN 
(1:1:1.4) -135.7(2) 
-144.6(7) 1 
-69.3(14)) 2 
91(3) 1 
99(3) 2 -0(3) 38(2) 
122.8(7)1 
129.1(8)2 2.01(4) 
CFZ-NH+-SACC- (1:1) -137.0 (6) -158.4 (6) 89.7 (7) -12(7) 31 (4) 126.9 (6) 1.9 (1) 
CFZ-NH+-TRPTA2--
TRPTA-solvent 
(1:0.5:0.5:x) 
143.09(13) -150.77(14) 83.78(14) -3(1) -28(1) 125.53(10) 1.91(3) 
CFZ-NH+-TRPTA2--
TRPTA (1:0.5:0.5) 
-148.7(2) -166.14(17) 97.32(18) 7(2) 24(2) 124.72(14) 1.97(3) 
CFZ-NH+-Cl--H2O 
(1:1:0.13) -149.1(2) 
-92.2(3) 1 
-137(1) 2 76.0(2) 13(2) 11(2) 
125.7(2) 1 
118.2(5) 2 2.04(3) 
CFZ-NH+-Cl- (1:1) 145.9(9) -149(1) 97(1) -13(5) -10(10) 123(1) 1.7(2) 
CFZ-NH+-MSA- (1:1) 146.5(3) -71.6(4) 85.4(4) 2(2) -19(2) 125.9(3) 1.83(4) 
CFZ-NH+-MLE- (1:1) -147.2(5) -100.9(6) 92.8(5) 7(4) 25(3) 125.0(4) 1.98(6) 
CFZ-NH+-INA- (1:1) -138.5(4) -168.5(3) 101.2(4) -6(2) 21(2) 125.6(3) 1.72(4) 
CFZ-NH+-NA- (1:1) A: 142.3(4) 
B: 150.3(4) 
A: -75.8(5) 
B: -71.0(5) 
A: 77.1(4) 
B: 81.4(4) 
A:-10.8 
B: -6.2 
A: -5.5 
B: -5 
A: 110.5(3) 
B: 124.3(3) 
A: 1.7938 
B: 1.7956 
CFZ-NH+-MLN- (1:1) -145.9(3) -158.0(3) 102.1(3) 1(2) 32.86 125.0(2) 1.99(4) 
CFZ-NH+-SCL- (1:1) 175.5(2) -153.5(3) 97.9(2) -8(2) -3(2) 125.1(2) 1.92(4) 
CFZ-NH+-CIT- (1:1) A: 145.9(3) B: -133.7(3  
A: -80.1(3) 
B:-160.6(3) 
A: 89.6(3) 
B:108.1(3) 
A: 5.0 
B: 7.6 
A:-10.0 
B: 0.3 
A: 125.6(2) 
B: 110.8(2) 
A: 1.8315 
B: 1.8583 
CFZ-NH+-FA- (1:1) -124.4(2) -146.0(3) 76.1(2) -8(2) 34(2) 126.02(18) 1.96(4) 
CFZ-NH+-SA- (1:1) 153.0(2) -83.6(3) 86.3(2) 0(2) -16(2) 125.5(2) 1.88(4) 
CFZ optimized -151.32 -156.44 91.63 / 5.62 121.01 / 
CFZ-NH+ optimized -122.86 -159.84 94.07 15.40 51.35 125.71 2.106 
CFZ-NH+-Cl- (1:1) 
optimized 147.26 -151.56 94.71 -3.41 -11.34 125.56 1.793 
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Table S4 Atomic coordinates of optimized clofazimine (DAKXUI03).  
E (RM06): -2180.82541943 Hartree 
center number atomic number atomic type X (Å) Y (Å) Z (Å) 
1 17 0 8.542442 0.704357 0.209214 
2 17 0 -6.9481 -2.29036 0.301462 
3 7 0 -2.14619 1.164776 -0.00064 
4 7 0 0.140856 2.748417 -0.17926 
5 7 0 2.923027 -1.14088 -0.07092 
6 1 0 2.783777 -2.15045 -0.13693 
7 6 0 -2.28458 2.547588 -0.08207 
8 7 0 0.835378 -2.65978 -0.00311 
9 6 0 -1.1053 3.314653 -0.17091 
10 6 0 -3.85825 0.03082 1.308589 
11 1 0 -3.3956 0.426814 2.209955 
12 6 0 1.547901 0.863029 -0.11714 
13 1 0 2.373254 1.560195 -0.21463 
14 6 0 -0.7402 -0.79419 0.042316 
15 1 0 -1.60785 -1.44215 0.100702 
16 6 0 0.561329 -1.40182 0.001783 
17 6 0 -4.9809 -0.77869 1.383768 
18 1 0 -5.42362 -1.03208 2.34267 
19 6 0 0.249921 1.451792 -0.10542 
20 6 0 -2.44695 5.326122 -0.25025 
21 1 0 -2.51705 6.408721 -0.31543 
22 6 0 -3.31285 0.341952 0.072493 
23 6 0 -3.53125 3.17529 -0.08004 
24 1 0 -4.44065 2.583892 -0.01418 
25 6 0 1.735017 -0.48293 -0.05268 
26 6 0 6.878357 0.175384 0.133305 
27 6 0 4.226038 -0.65292 -0.00281 
28 6 0 5.89341 0.914076 0.766634 
29 1 0 6.161099 1.809141 1.321564 
30 6 0 -1.21549 4.708614 -0.25385 
31 1 0 -0.28766 5.271267 -0.32133 
32 6 0 -0.90753 0.555862 -0.01269 
33 6 0 -5.53832 -1.26958 0.212642 
34 6 0 -3.87643 -0.15388 -1.09399 
35 1 0 -3.42727 0.09907 -2.05206 
36 6 0 -4.9974 -0.96589 -1.0281 
37 1 0 -5.45329 -1.36314 -1.93033 
38 6 0 -0.2188 -3.65343 0.025556 
39 1 0 -1.04819 -3.32944 0.68098 
40 6 0 5.238034 -1.38892 -0.62419 
41 1 0 4.975503 -2.28888 -1.17732 
42 6 0 -3.60499 4.553147 -0.1635 
43 1 0 -4.58073 5.032876 -0.16135 
44 6 0 4.573377 0.499034 0.704977 
45 1 0 3.814891 1.056259 1.245423 
46 6 0 6.557893 -0.98367 -0.55595 
47 1 0 7.339542 -1.55883 -1.04455 
48 6 0 -0.76555 -3.87152 -1.37932 
49 1 0 -1.20876 -2.95781 -1.79154 
50 1 0 0.045264 -4.18105 -2.04986 
51 1 0 -1.531 -4.65621 -1.38624 
52 6 0 0.348687 -4.94272 0.588143 
53 1 0 1.160856 -5.30783 -0.05236 
54 1 0 0.759522 -4.78602 1.590701 
55 1 0 -0.4186 -5.7233 0.648061 
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Table S5 Atomic coordinates of optimized geometry of clofaziminium without any counter-ion. 
E(RM06): -2181.23130054 Hartree 
center number atomic number atomic type X (Å) Y (Å) Z (Å) 
1 17 0 7.056535 -1.83325 -0.10889 
2 17 0 -8.29076 0.831069 -0.25532 
3 7 0 1.986052 1.21845 0.016537 
4 7 0 -0.41207 2.611798 0.094537 
5 7 0 -2.87044 -1.49724 0.280427 
6 1 0 -2.8273 -2.2254 0.987232 
7 7 0 -0.57662 -2.84764 -0.11481 
8 1 0 -1.50507 -3.19261 -0.33617 
9 6 0 3.202897 3.331344 0.012594 
10 1 0 4.1611 2.821471 -0.00925 
11 6 0 3.14538 4.704976 0.027658 
12 1 0 4.072743 5.271274 0.015633 
13 6 0 1.917066 5.389851 0.05962 
14 1 0 1.906057 6.475633 0.069725 
15 6 0 0.745516 4.685901 0.080842 
16 1 0 -0.22634 5.17041 0.109056 
17 6 0 0.759909 3.274028 0.06823 
18 6 0 -0.40737 1.298616 0.083144 
19 6 0 -1.64479 0.601186 0.163243 
20 1 0 -2.54262 1.205452 0.256108 
21 6 0 -1.69997 -0.75572 0.171512 
22 6 0 -0.46629 -1.51892 0.014856 
23 6 0 0.762381 -0.86201 0.002342 
24 1 0 1.678887 -1.43236 -0.08841 
25 6 0 0.813821 0.524543 0.038123 
26 6 0 2.00929 2.598854 0.029963 
27 6 0 3.230027 0.488114 -0.01457 
28 6 0 3.827216 0.216216 -1.23502 
29 1 0 3.366348 0.567761 -2.15574 
30 6 0 5.012574 -0.50068 -1.26552 
31 1 0 5.502925 -0.72341 -2.20855 
32 6 0 5.576774 -0.935 -0.07274 
33 6 0 4.976537 -0.65873 1.149448 
34 1 0 5.440162 -1.00187 2.06956 
35 6 0 3.792289 0.059804 1.17759 
36 1 0 3.30424 0.290501 2.122241 
37 6 0 -4.1561 -0.90832 0.167068 
38 6 0 -4.5193 -0.24492 -1.0016 
39 1 0 -3.8097 -0.16646 -1.82247 
40 6 0 -5.78504 0.297301 -1.12814 
41 1 0 -6.07633 0.81429 -2.03792 
42 6 0 -6.69797 0.159085 -0.09073 
43 6 0 -6.35278 -0.51263 1.070791 
44 1 0 -7.07718 -0.61536 1.873451 
45 6 0 -5.07632 -1.03648 1.200261 
46 1 0 -4.79583 -1.54926 2.119174 
47 6 0 0.536842 -3.78589 -0.29436 
48 1 0 1.238437 -3.33726 -1.0157 
49 6 0 -0.01156 -5.06698 -0.88611 
50 1 0 -0.73028 -5.53593 -0.20219 
51 1 0 0.794397 -5.78635 -1.05265 
52 1 0 -0.50696 -4.89353 -1.84702 
53 6 0 1.247951 -4.03899 1.023846 
54 1 0 1.622656 -3.11914 1.485166 
55 1 0 2.101326 -4.70757 0.872355 
56 1 0 0.567728 -4.51828 1.736968 
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Table S6 Atomic coordinates of optimized geometry of clofaziminium with Cl- counter-ion 
(LABQUD). E(RM06): -2641.64794122 Hartree 
center number atomic number atomic type X (Å) Y (Å) Z (Å) 
1 17 0 -3.27379 -3.89917 -0.38225 
2 7 0 0.095202 2.936519 -0.43037 
3 6 0 3.757824 3.303799 -0.11117 
4 1 0 4.649915 2.701454 0.035816 
5 17 0 -8.09389 1.673677 0.586502 
6 7 0 2.334504 1.319351 -0.09732 
7 6 0 2.713893 5.464003 -0.40772 
8 1 0 2.810042 6.543039 -0.49229 
9 7 0 -0.533 -2.49977 -0.3261 
10 17 0 7.031537 -2.22103 0.588543 
11 6 0 1.477936 4.87299 -0.48096 
12 1 0 0.566891 5.448656 -0.62117 
13 7 0 -2.78412 -0.84749 -0.14344 
14 6 0 1.337 3.476707 -0.37178 
15 1 0 -2.91335 -1.87072 -0.25096 
16 6 0 2.50132 2.695225 -0.19041 
17 6 0 1.100736 0.741508 -0.17869 
18 6 0 -0.04056 1.634336 -0.32635 
19 6 0 0.909135 -0.61941 -0.14209 
20 1 0 1.767179 -1.27377 -0.05894 
21 6 0 -1.32675 1.055277 -0.34656 
22 1 0 -2.15329 1.749207 -0.44986 
23 6 0 -1.55473 -0.29498 -0.23405 
24 6 0 -0.37642 -1.19263 -0.23385 
25 6 0 -4.01235 -0.18451 0.028548 
26 6 0 -5.13582 -0.75764 -0.56983 
27 1 0 -5.0168 -1.66719 -1.15531 
28 6 0 -6.38655 -0.19398 -0.39573 
29 1 0 -7.26117 -0.63977 -0.86074 
30 6 0 -6.51852 0.947152 0.379402 
31 6 0 -4.16833 0.944026 0.832816 
32 1 0 -3.31778 1.365247 1.360611 
33 6 0 3.48509 0.476738 0.06962 
34 6 0 3.867293 0.090829 1.344782 
35 1 0 3.300615 0.441189 2.204705 
36 6 0 4.962601 -0.74222 1.508536 
37 1 0 5.27952 -1.05787 2.498183 
38 6 0 5.657784 -1.17419 0.387891 
39 6 0 4.181193 0.042924 -1.04758 
40 1 0 3.8581 0.357686 -2.03754 
41 6 0 -5.41897 1.513459 1.002824 
42 1 0 -5.54386 2.391144 1.630882 
43 6 0 5.278596 -0.78842 -0.89006 
44 1 0 5.839203 -1.14029 -1.75107 
45 6 0 0.54871 -3.4903 -0.33039 
46 1 0 1.412921 -3.04428 -0.84218 
47 6 0 0.917983 -3.84915 1.099768 
48 1 0 1.246471 -2.97446 1.673051 
49 1 0 1.724537 -4.59028 1.114467 
50 1 0 0.048181 -4.28132 1.608237 
51 6 0 0.103184 -4.70726 -1.11753 
52 1 0 -0.18416 -4.43898 -2.13881 
53 1 0 -0.7644 -5.18499 -0.65038 
54 1 0 0.921459 -5.43324 -1.16594 
55 6 0 3.85547 4.674 -0.21969 
56 1 0 4.834138 5.142751 -0.1577 
57 1 0 -1.47856 -2.94228 -0.34855 
E(RM06): -2641.64794122 Hartree 
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Figure S1 . Powder patterns of (a), from bottom to top, CFZ, FA, CFZ/FA LAG MeCN batch 
powder and  CFZ-NH+FA- (1:1) calculated pattern from SCXRD data, (b)  CFZ, SA, CFZ/SA LAG 
MeCN batch powder and CFZ-NH+-SA- (1:1) calculated pattern from SCXRD data, (c) CFZ, SACC, 
CFZ/SACC LAG MeCN batch powder and  CFZ-NH+-SACC- (1:1) and CFZ-NH+-SACC--MeCN 
(1:1:1.4) calculated patterns from SCXRD data, (d) CFZ, 2,4-DHBA, CFZ/2,4-DHBA LAG MeOH 
batch powder and CFZ-NH+-2,4DHBA--MeOH (1:1:1) calculated pattern from SCXRD data. 
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Figure S2 . Powder patterns of (a), CFZ, DL-MAL and CFZ/DL-MAL LAG MeCN batch powder, 
(b) CFZ, L-ASP, CFZ/L-ASP LAG MeCN batch powder, (c) CFZ, TRPTA, CFZ/TRPTA LAG 
EtOAc, CFZ-NH+-TRPTA2--TRPTA-solvent (1:0.5:0.5:x) calculated pattern from SCXRD data, 
CFZ/TRPTA LAG EtOAc batch powder at 25°C after heating to 200°C and CFZ-NH+-TRPTA2--
TRPTA (1:0.5:0.5) calculated from SCXRD data, (d) CFZ, CIT, CFZ-NH+-CIT- (1:1) calculated 
from SCXRD data (Bannigan et al., 2017), CFZ/CIT 2/1 LAG MeOH/MeCN 50/50, CFZ-CIT 2/1 
calculated from SCXRD data obtained at 100K (structure intrinsically disordered) and CFZ/CIT 3/1 
LAG MeOH/MeCN 50/50. * SCXRD data from cif file available in the publication of Bannigan et al. 
(Bannigan et al., 2017). 
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Figure S3 (a)Variable temperature powder X-ray diffraction of CFZ/TRPTA LAG EtOAc batch powder and comparison with calculated pattern of CFZ-
NH+-TRPTA2--TRPTA (1:0.5:0.5). Desolvatation of a solvated crystalline powder occurred to give a non-solvated crystalline powder matching the 
calculated powder pattern of CFZ-NH+-TRPTA2--TRPTA (1:0.5:0.5). (b) Zoom on the 5-15° 2𝜃 region, disappearing peak upon heating at 2𝜃 value of 7.7° 
highlighted by plain line frame, appearing peaks upon heating at 2𝜃 values of 8.8 and 9.2° (dashed frame) as well as 11.5 and 12.0° (dotted frame). 
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Figure S4 Channel arrangement and solvent accessible voids in the structure of CFZ-NH+-
TRPTA2--TRPTA-solvent (1:0.5:0.5:x) (view along a-axis) (a)  and in the one of CFZ-NH+-
TRPTA2--TRPTA (1:0.5:0.5) (view along a-axis) (b). 
 
Figure S5 Effect of different solvents while grinding (a) CFZ with FA, (b) CFZ with SA, (c) CFZ 
with SACC.  
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Figure S6 Effect of different solvents while grinding (a) CFZ with TRPTA, (b) CFZ with CIT in 
1/1 molar ratio, (c) CFZ with CIT in 2/1 molar ratio and (d) CFZ with CIT in 3/1 molar ratio. 
Liquid-assisted grinding experiments were performed in three solvents (MeCN, MeOH and EtOAc) 
for all combinations described in this paper. For the unsolvated salts, changing the solvent during 
grinding experiment does not affect the output of the reaction. Instead, for solvated salts, indeed, the 
powder pattern change in function of the solvent using during liquid-assisted grinding. 
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Figure S7 Hirshfeld surface analysis (red regions highlighting close contacts), 2D-fingerprint plots 
(based on the surface generated on the molecules/ions present in the asymmetric unit) and percentage 
contribution to the Hirshfeld surface area for the different close contacts in the structures of (a) CFZ-
NH+-FA- (1:1) (b) CFZ-NH+-SA- (1:1), (c) CFZ-NH+-SACC--MeCN (1:1:1.4), (d) CFZ-NH+-
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SACC-(1:1), (e) CFZ-NH+-2,4DHBA--MeOH (1:1:1) and (f) CFZ-NH+-TRPTA2--TRPTA 
(1:0.5:0.5).  
Hirshfeld surfaces and fingerprint plots of de (distance from the surface to the nearest atoms outside 
the surface) vs. di (distance from the surface to the nearest atoms located inside the surface) were 
generated using CrystalExplorer (version 17.5) (Turner et al., 2017; Spackman & Jayatilaka, 2009; 
Spackman & Mckinnon, 2002; Hirshfeld, 1977). Surfaces were generated using the normalized 
contact distance ‘dnorm’ descriptor (Mckinnon et al., 2007). White surfaces correspond to contacts with 
distance around the sum of van der Waals radii while red and blue surfaces highlight shorter and 
longer contacts respectively (Mckinnon et al., 2007). For the structure of CFZ-NH+-SA- (1:1) 
disorder of SA- was removed (and occupancies of C29A, H29A, H29B, C30A, H30A and H30B were 
modified from 0.739 to 1) for surface and fingerprint plots generation. For the structure of CFZ-
NH+2,4DHBA--MeOH (1:1:1) 2,4DHBA- and MeOH disorder was removed and corresponding 
occupancies were modified to 1. Concerning the structure of CFZ-NH+-SACC--MeCN (1:1:1.4) 
MeCN is disordered over three position, with positions of C37-C38-N7 being very close to the ones of 
C37A-C38A-N7A. In consequence, one MeCN molecule (C37A-H37D-H37E-H37F-C38A-N7A) 
was removed and occupancies of C37-H37A-H37B-H37C-C38-N7 were modified accordingly 
(occupancies of 0.464 modified to 0.953 (which is the sum of the occupancies of C37A-H37D-H37E-
H37F-C38A-N7A and C37-H37A-H37B-H37C-C38-N7). Disorder of isopropyl of CFZ was also 
removed and occupancies of C25B-H25B-C26B-H26D-H26E-H26F-C27B-H27D-H27E-H27F were 
modified to 1 before Hirshfeld surface and 2D fingerprint plots generation. In the structure of CFZ-
NH+-SACC- (1:1:), SACC- is disordered and second position of SACC was removed (and 
occupancies were modified to 1 for the remaining SACC position) prior Hirshfeld surface and 2D 
fingerprint plots generation. 2D-fingerprint plots shown on Figure S7 corresponds to the Hirshfeld 
surface generated by selecting all atoms from the unit cell (for CFZ-NH+-TRPTA2--TRPTA 
(1:0.5:0.5), Hirshfeld surface was generated on CFZ-NH+-TRPTA2--TRPTA-CFZ-NH+ (1:1:1:1) 
assembly which corresponds to a charge balanced assembly).  
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